what is durvalumab
What is Durvalumab? Durvalumab is an investigational human monoclonal antibody directed against the programmed cell death ligand 1 (PD-L1) protein. Signals from PD-L1 help tumours avoid detection by the immune system. Durvalumab blocks these signals, countering the tumourâs immune-evading tactics. The antibody belongs to an emerging class of immunotherapies commonly referred to as checkpoint inhibitors, because they remove checks the body places on immune activation.